Targets › KMT2D
1 program from 1 company in 7 trials: 4 Phase 1, 3 Phase 2; Oncology; next expected readout Nov 2026.
Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4). Part of chromatin remodeling machinery predominantly forms H3K4me1 methylation marks at active chromatin sites where transcription and DNA repair take place. (UniProt, O14686)
Open in Phaseline: the race on KMT2D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Treeline Biosciences | zeprumetostat (TLN-254) EZH2 inhibitor | KMT2D | Phase 1 | Lymphoma; Peripheral T Cells Lymphoma (PTCL); Bladder Urothelial Carcinoma; Follicular Lymphoma … | Nov 2026 |
Lymphoma (2) Peripheral T Cells Lymphoma (PTCL) (1) Bladder Urothelial Carcinoma (1) Follicular Lymphoma (1) Extranodal NK/T-cell Lymphoma (1) Large Granular Lymphocyte Leukemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.